Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets: 2017-2025

Historic Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Current Assets rose 27.77% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 27.77%. This contributed to the annual value of $1.4 billion for FY2024, which is 139.55% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Current Assets of $1.1 billion as of Q3 2025, which was down 7.89% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Current Assets peaked at $1.4 billion during Q4 2024, and registered a low of $157.8 million during Q1 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Current Assets averaged around $855.9 million, with its median value being $877.6 million (2024).
  • In the last 5 years, Crinetics Pharmaceuticals' Current Assets crashed by 31.58% in 2023 and then spiked by 207.14% in 2024.
  • Crinetics Pharmaceuticals' Current Assets (Quarterly) stood at $344.7 million in 2021, then climbed by 0.13% to $345.2 million in 2022, then skyrocketed by 66.33% to $574.2 million in 2023, then skyrocketed by 139.55% to $1.4 billion in 2024, then grew by 27.77% to $1.1 billion in 2025.
  • Its Current Assets was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.